Ajanta Pharma Limited (AJANTPHARM) — Corporate Action | 30 July 2026(2 announcements)
Ajanta Pharma announced that August 5, 2026 will be the record date for determining shareholders eligible to receive its first interim dividend, as required under SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015.
Ajanta Pharma announced a 1st interim dividend of Rs. 32 per share (Rs. 400 cr. total) for FY27, payable after 18 August 2026, with record date on 5 August 2026. The Board approved this during its 30 July 2026 meeting, alongside Q1 FY27 results showing 25% revenue growth to Rs. 1,626 cr. and 31% PAT growth to Rs. 334 cr. The company highlighted strong performance across Branded Generics, US Generics, and Africa segments, with Branded Generics contributing 66% of total revenue. The dividend reflects robust cash generation and commitment to shareholder returns amid consistent growth trends.
About Ajanta Pharma Limited (AJANTPHARM)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
📡 Get AI alerts when AJANTPHARM files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track AJANTPHARM — Free💡 Ask AI about this filing
📊 More AJANTPHARM filings
- 🔴 Financial Results — 21 July 2026 Ajanta Pharma announced a revised timing for its Q1 FY2027 earnings conference call, now scheduled f...
- 🔴 Financial Results — 20 July 2026 Ajanta Pharma announced its Q1 FY2027 unaudited financial results will be released on 30 July 2026 a...
- 🟡 Board Meeting — 16 July 2026 Ajanta Pharma held its 47th Annual General Meeting on 16 July 2026 via video conference, where share...
- Announcement — 2 July 2026 Ajanta Pharma announced that its Paithan manufacturing facility in Maharashtra received a Voluntary ...
- Financial Results — 26 June 2026 Ajanta Pharma announced that its trading window will close on 1 July 2026 for insider transactions u...
🔥 Also filed on 30 July 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when AJANTPHARM files new disclosures
Track AJANTPHARM filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track AJANTPHARM — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research